PricewaterhouseCoopers Inc

Psychedelic-Enhanced Therapy Business For Sale

Business for Sale / Investors Sought

PricewaterhouseCoopers Inc., LIT (“PwC”), in its capacity as the Court-appointed monitor (the “Monitor”) of:

Field Trip Health & Wellness Ltd., Field Trip Health Holdings Inc., Field Trip Health Canada Inc., Field Trip Digital Canada Inc., and Field Trip Health USA Inc. (collectively, “Field Trip” or the “Company”)

is launching a Court-approved sale and investment solicitation process (“SISP”) for the purpose of soliciting proposals to purchase or invest in some or all of Field Trip’s assets, business and operations. Field Trip is a leader in the development and delivery of psychedelic-enhanced therapies. The Company currently operates four clinics across Canada (Toronto, Vancouver) and the United States (New York, Santa Monica).

In order to obtain detailed information on Field Trip, interested parties will be required to sign a non-disclosure agreement. The deadline for submitting a binding offer is April 24, 2023 at 5:00 p.m. ET.

For further information, please refer to www.pwc.com/ca/fieldtrip or contact at ca_fieldtrip@pwc.com.

PricewaterhouseCoopers Inc., LIT
Monitor of Field Trip Health & Wellness Ltd., Field Trip Health Holdings Inc.,
Field Trip Health Canada Inc., Field Trip Digital Canada Inc., and Field Trip Health USA Inc.
18 York Street, Suite 2600
Toronto, ON M5J 0B2
Email: ca_fieldtrip@pwc.com

The Conversation (0)
Glowing mushrooms with colorful graphs in the background on a dark surface.

US Policy Momentum, Clinical Progress Fueling Psychedelics Market in 2025

When the US Food and Drug Administration (FDA) rejected Lykos Therapeutics’ new drug application for MDMA-assisted therapy last August, the initial disappointment cast a shadow over the psychedelics industry.

However, the sector is seeing a resurgence of optimism in 2025 on the back of various US developments.

“The psychedelic industry in 2025 will likely see significant advancements in clinical applications, particularly in treating PTSD, depression, and addiction, as research continues to validate their therapeutic potential,” Dr. Markus Ploesser, chief innovation officer at Open Mind Health, told Microdose in January.

Keep reading...Show less
AVECHO BIOTECHNOLOGY

Avecho and Sandoz enter Exclusive License and Development Agreement to Commercialise CBD for Insomnia in Australia

Avecho Biotechnology Limited (ASX: AVE) (“Avecho” or the “Company”) today announced it has signed an exclusive ten-year development and licensing agreement with Sandoz Group AG (“Sandoz”) for the commercial rights to Avecho’s Phase III cannabidiol (“CBD”) capsule for insomnia in Australia. Avecho retains the rights to commercialise the product in all other territories, with Sandoz granted a first right of refusal for these markets. Avecho’s CBD capsule aims to be the first pharmaceutical CBD product registered with the Therapeutic Goods Administration (“TGA”) as an over-the-counter medicine, which market forecasts predict could generate sales surpassing US$125M per annum in Australia2.

Keep reading...Show less

Compass Pathways to announce fourth quarter and year-end financial results on February 27th, 2025

Compass management will host a conference call at 8:00 am ET (1:00pm UK)

News Provided by Business Wire via QuoteMedia

Keep reading...Show less
Emyria Limited

Emyria and UWA in Partnership to Commercialise Novel Serotonin-Releasing Agents for Mental Health and Neurology

Emyria Limited (ASX: EMD) (“Emyria”, or the “Company”) has signed an exclusive licence agreement with UWA, granting worldwide rights to a rapidly growing portfolio of selective serotonin-releasing agents. (See Appendix for Key Commercial Terms). These novel compounds, realised through a UWA–Emyria research partnership launched in 2021,2 include potential next-generation treatments for mental health and neurological conditions such as PTSD and Parkinson’s disease.

Keep reading...Show less
Quantum Biopharm (CSE: QNTM)

Quantum BioPharma Files a US Federal Lawsuit Against CIBC World Markets, RBC Dominion Securities and Others, Seeking Damages in Excess of $700,000,000 USD, for Possible Stock Price Manipulation/Spoofing

Christian Attar Law Firm and Freedman Normand Friedland LLP, in conjunction with forensic investigators, have uncovered evidence of a potential multi-year market manipulation scheme that has caused substantial damages to the Company and its shareholders


Keep reading...Show less

Latest Press Releases

Related News

×